✦ LIBER ✦

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

✍ Scribed by David A. Reardon; Annick Desjardins; Katherine Peters; Sridharan Gururangan; John Sampson; Jeremy N. Rich; Roger McLendon; James E. Herndon; Jennifer Marcello; Stevie Threatt; Allan H. Friedman; James J. Vredenburgh; Henry S. Friedman

Publisher: Springer US
Year: 2010
Tongue: English
Weight: 230 KB
Volume: 103
Category: Article
ISSN: 0167-594X
DOI: 10.1007/s11060-010-0403-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 study of carboplatin, irinotecan

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

✍ David A. Reardon; Annick Desjardins; Katherine B. Peters; James J. Vredenburgh; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB

Phase II study of carboplatin, irinoteca

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

✍ David A. Reardon; Annick Desjardins; Katherine B. Peters; Sridharan Gururangan; 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 736 KB

Phase II study of accelerated fractionat

Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme

✍ V.A. Levin; M.H. Maor; P.F. Thall; W.K.A. Yung; J. Bruner; R. Sawaya; A.P. Kyrit 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 1000 KB

Second-line treatment with carboplatin f

Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy : A Phase II study

✍ Riccardo Soffietti; Mauro Nobile; Roberta Rudà; Marzia Borgognone; Alessandra Co 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

## Abstract ## BACKGROUND The efficacy of second‐line chemotherapy for patients with recurrent or progressive oligodendroglial tumors is limited. In the current study, the authors investigated the use of carboplatin as a second‐line chemotherapeutic agent against these types of tumors. ## METHODS

Final results of a phase II study ofnab-

Final results of a phase II study ofnab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

✍ Christopher Lobo; Gilberto Lopes; Odalys Baez; Aurelio Castrellon; Annapoorna Fe 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 268 KB

Doublet regimen of cisplatin plus doceta

Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study

✍ Takashi Seto; Yoriko Takezako; Hiroko Nakamura; Kayo Takeda; Fumiko Inoue; Hiros 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 193 KB